-
CFDA SE Cell Tracer Kit: Practical Guide
2026-09-25
The CFDA SE Cell Tracer Kit provides covalent fluorescent labeling for tracking cell populations through cell proliferation studies and lineage tracing. Use it when persistent labeling is needed; it is not suited to reversible labels or real-time monitoring of physiological changes.
-
CNQX: AMPA/Kainate Antagonism in Neural Circuits
2026-09-25
CNQX, also known as 6-cyano-7-nitroquinoxaline-2,3-dione, is a competitive AMPA and kainate receptor antagonist used to investigate excitatory synaptic signaling. In a rat cNTS–PVN cardiovascular study, CNQX did not reproduce the attenuation observed with an NMDA receptor antagonist, illustrating how receptor-selective tools can distinguish circuit mechanisms.
-
PD 0332991: A Genomic Gate for CDK4/6 Studies
2026-09-24
PD 0332991 (Palbociclib HCl) is a selective CDK4/6 inhibitor, but its effects depend on an intact downstream Rb pathway. This article connects mesothelioma genomics to practical assay design, showing how RB1 status can shape—not predetermine—a research response.
-
Simvastatin (Zocor): Applied Research Workflows
2026-09-24
Use Simvastatin to connect HMG-CoA reductase inhibition with measurable lipid-metabolism and hepatic cancer-cell phenotypes. This guide covers stock preparation, dose selection, orthogonal readouts, and practical controls—while separating established statin biology from methods borrowed from neuronal stress research.
-
A23187, Free Acid: From Calcium Flux to Translation
2026-09-23
A mechanistic and translational guide to using A23187, free acid as a calcium ionophore for separating intracellular calcium signaling, mitochondrial apoptosis, ROS generation, and genuine cell killing from nonspecific viability loss.
-
Linoleic Acid Workflows for Oxidative Stress
2026-09-23
Linoleic Acid provides a defined C18:2(9Z,12Z) stimulus for oxidative stress, erythrocyte injury, membrane, migration, and deficiency studies. This guide connects practical dosing and handling decisions with the AMPK–MNK–P-eIF4E biology reported in fasting and ketogenic-diet research.
-
BKT140 (BL-8040) CXCR4 Antagonist
2026-09-22
BKT140, also called BL-8040 and TF 14016, is an orally bioavailable CXCR4 antagonist for oncology research. It supports studies of CXCR4-mediated chemotaxis inhibition, tumor-cell survival, apoptosis induction, and hematopoietic stem cell mobilization.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-21
A 2025 GeroScience study developed a drug-sensitized Saccharomyces cerevisiae platform that detects TOR pathway inhibitors at substantially lower concentrations than a wild-type yeast background. The system identified activity from Torin1, omipalisib, AZD8055, and aminophylline while finding no evidence of TOR inhibition for several tested compounds, including Canagliflozin.
-
Gingerenone A Re-sensitizes RCC to Sunitinib
2026-09-21
The reference study identifies gingerenone A as a metabolic intervention that targets LDHA-driven glycolysis and restores sunitinib responsiveness in renal cell carcinoma models. Its combination of computational target discovery, metabolic rescue experiments, drug-combination analysis, and in vivo validation supports a mechanistic link between glycolytic suppression, HIF-1α signaling, and resistance reversal.
-
Linoleic Acid (C18:2) Protocol and QC Guide
2026-09-20
Linoleic Acid (SKU C3108) provides a defined C18:2(9Z,12Z) fatty acid input for oxidative stress, membrane, erythrocyte, migration, and nutritional deficiency workflows. It is water-insoluble, requires an ethanol- or DMSO-based preparation, and should be used freshly rather than from long-stored solutions.
-
AKT Inhibitors: Mechanisms, Resistance, and Combinations
2026-09-19
Kostaras and colleagues systematically compared ATP-competitive and allosteric AKT inhibitors using biochemical, cellular, structural, and phosphoproteomic approaches. Their findings show that inhibitor class, AKT isoform, mutation status, and non-catalytic signaling can strongly shape drug response, providing a framework for rational combination studies.
-
Pazopanib Hydrochloride: Smarter In Vitro Assays
2026-09-19
Build more informative oncology experiments with Pazopanib Hydrochloride by separating growth arrest from true cell killing. This workflow combines target-aware dosing, time-resolved viability measurements, and practical troubleshooting for renal cell carcinoma, soft tissue sarcoma, and angiogenesis models.
-
Alternariol and Liver Fibrosis: Study Insights
2026-09-18
The reference study shows that Alternariol (AOH) and alternariol monomethyl ether can drive LX-2 hepatic stellate cells toward a contractile, myofibroblast-like phenotype, whereas tenuazonic acid produced no significant response in the reported model. By combining lncRNA-mRNA omics with pathway analysis, the work connects Alternaria-toxin exposure with NF-κB activation, ferroptosis, and AMPK/AKT/mTOR-related autophagy, while also examining CotA laccase as a possible AOH detoxification strategy.
-
Coronavirus Macrodomain Counters PARP Antiviral Defense
2026-09-18
Grunewald et al. showed that coronavirus macrodomains protect viral replication by counteracting PARP-dependent restriction and interferon induction. Pharmacologic inhibition and PARP12/PARP14 depletion connected ADP-ribosylation with antiviral immunity, providing a mechanistic framework for studying coronavirus host–virus interactions.
-
Tunable Human Intestinal Organoids: Study Insights
2026-09-17
The reference study develops a human small-intestinal organoid system that maintains strong proliferation while expanding epithelial cell diversity under a unified culture condition. Its central advance is a tunable strategy that strengthens stem-cell potential first, then uses Wnt, Notch, BMP, and BET-related perturbations to bias differentiation in reversible or lineage-directed ways.